What moat does Laboratorios Farmacéuticos Rovi have?

The advantage is the sterile-filling plant already authorised and the heparin position already sold into hospitals. Authorising the plant takes years. It is not a monopoly on the medicine. The moat narrows if the heparin price falls, if a manufacturing contract is not renewed, or if someone else's new capacity is spare.

How do you read the Laboratorios Farmacéuticos Rovi radar?

Health has to be read in cash and debt, not as if the short blurb had closed the balance sheet. Quality separates the heparin margin, which is more recurring, from third-party manufacturing, which depends on the contract. Growth is volume and the next order, not a software curve. P/E valuation mixes the two trades. Shareholder return is the dividend, secondary if cash goes into the plant.

Which multiples matter for Laboratorios Farmacéuticos Rovi?

The P/E of a year with one large manufacturing contract is not normal earnings. EV/EBITDA is read knowing which part is heparin and which part is a contract. The margin of a full year is not the margin when the contract ends. Do not compare it with Johnson & Johnson. A dash means the ROVI.MC cache is cold.

What does this Laboratorios Farmacéuticos Rovi analysis leave out?

Not advice on ROVI.MC. Vaultflake does not audit a plant or a heparin price. This is not a share and not an inventory of contracts. Read the CNMV filings. A past dividend is not a right. The table is a snapshot, not a target price.

Laboratorios Farmacéuticos Rovi (ROVI.MC) analysis

Laboratorios Farmacéuticos Rovi, S.A.

Sector:Health Care · Heparin and Contract Manufacturing

Country:Spain

Profile and moat

Rovi has two trades. One is low-molecular-weight heparin: a medicine with a price and a volume, and with a price the regulator can move. The other is manufacturing for other companies, chiefly sterile filling of vaccines and biologics. A manufacturing contract ends. A large customer in one year is not the book of the next.

It is not Grifols. There the asset is the plasma network and the fractionation licence. Here it is the filling plant and the heparin product. It is not a patent on one molecule that lasts as long as the document. This report does not state a heparin share and does not say the balance sheet is free of debt.

The dividend comes from the cash the two businesses leave. If a manufacturing contract is not renewed, that cash changes. This report does not state a calendar.

Laboratorios Farmacéuticos Rovi (ROVI.MC) analysis

Laboratorios Farmacéuticos Rovi, S.A.

Sector:Health Care · Heparin and Contract Manufacturing

Country:Spain

Profile and moat

The dividend comes from the cash the two businesses leave. If a manufacturing contract is not renewed, that cash changes. This report does not state a calendar.

Laboratorios Farmacéuticos Rovi (ROVI.MC) analysis

Profile and moat

Laboratorios Farmacéuticos Rovi (ROVI.MC) analysis

Profile and moat

Radar axes

Limits of this report

Questions from this report

What moat does Laboratorios Farmacéuticos Rovi have?

How do you read the Laboratorios Farmacéuticos Rovi radar?

Which multiples matter for Laboratorios Farmacéuticos Rovi?

What does this Laboratorios Farmacéuticos Rovi analysis leave out?

Related reports in Health Care · Heparin and Contract Manufacturing

Johnson & Johnson

Novo Nordisk A/S

UnitedHealth Group Incorporated

Eli Lilly and Company

AbbVie Inc.

Merck & Co., Inc.